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S206 Poster Session I(1-16). Median total CD34+/kg collected was 9.98  106 (2.55-
35.79). Twenty-six (25%) patients had prior radiation. Median age
was 54.4 years, range 29.7-66.1. Median days to neutrophil engraft-
ment was 11, range 1-16 post first transplant and 10 days (8-43) post
second transplant. Days to platelet independence after first trans-
plant was 13 days (0-71), and 12 days (0-44) after the second. We
found that time from diagnosis to collection (#7 months vs$ 7
months) impacted reaching the 6  106 CD34+ cells/kg within the
1-2 days target. Our analysis showed that patients apheresed \7
months from diagnosis were 2.6 times (CI: 1.14-5.95) more likely
to reach 6  106 CD34+/kg within the 1-2 days (p5 0.02). This re-
sult is comparable to those of DiPersio et al, Blood 113 (23):5720-
5726, 2009. Sixty-seven percent of our Cy-G patients reached 6 
106 CD34+/kg in 2 days vs 71.6% of DiPersio’s plerixafor-G pts.
Conclusion:CD34+ cell yield following Cy-Gmobilization is com-
parable to what could be obtained with plerixafor-G mobilization.
We suggest reserving plerixafor for patients with substantial delay
between diagnosis and apheresis and for those failing Cy-G mobili-
zation.129
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Introduction: Chemomobilization of autologous peripheral blood
stem cells (PBSCs) is costly and requires substantial resource alloca-
tions. This burden has considerable effects on patients (pts), pro-
viders and payers. We performed a retrospective study to evaluate
the difference in costs and effectiveness of first-line mobilization of
autologous PBSCs with cyclophosphamide (CY; 1.5-4 gm/
m2) + G-CSF (n5 34) versus plerixafor + G-CSF (n5 8) in pts
with non-Hodgkin’s lymphoma (NHL) between 6/2006 and 8/2009.
Methods: We created a decision analytic model to estimate the
mean costs and effectiveness rates for the two regimens. This model
incorporated the minimum acceptable CD34+ cell dose for autolo-
gous PBSC transplant (PBSCT) and also incorporated adverse
events such as clinically significant nausea and vomiting, anemia,
thrombocytopenia, and hospital admissions for neutropenic fever.
The analysis was conducted from the perspective of a managed
care organization and used published literature to identify drug, lab-
oratory, and apheresis costs. A treatment success was defined as ad-
equate CD34+ dose to proceed with autologous PBSCT. We
conducted a Monte Carlo simulation of 1,000 cases.
Results: Successful PBSC mobilization occurred in 24 of 34 pts
(70.6%) in the CY group and in 7 of 8 pts (87.5%) in the plerixafor
group. Nine of the 10 pts who failed CY proceeded to second-line
plerixafor. Two pts in the CY group and one pt in the plerixafor
group underwent allogeneic transplant after failing autologous
PBSC mobilization (estimated cost $400,000; not included in analy-
sis). For CY +G-CSF, the mean cost was $20,965 and the mean ef-
fectiveness was 0.71; for plerixafor + G-CSF, the mean cost was
$19,523 and the mean effectiveness was 0.87. TheMonte Carlo sim-
ulation showed overlap between the two regimens in the 95% confi-
dence intervals in both cost and effectiveness. The incremental
analysis demonstrated that plerixafor + G-CSF dominated CY +G-
CSF (i.e., plerixafor and G-CSF was more effective and less costly)
in 69.9% of cases.
Conclusion:This decision analytic model demonstrates that plerix-
afor + G-CSF is more cost-effective than CY +G-CSF for autolo-
gous PBSC mobilization in most pts with NHL. This analysis,
conducted from a managed care perspective, does not consider the
effects of the two PBSC mobilization strategies on the quality of
life in these pts. Similar decision analyses in pts undergoing PBSC
mobilization for myeloma could also be instructive.130
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Background:Cyclophosphamide (Cy) (2-7 g/m2) has been shown to
be an effective regimen for hematopoietic stem cell (HSC) mobiliza-
tion in Non-Hodgkin’s Lymphoma (NHL) patients undergoing au-
tologous stem cell transplantation (ASCT). However, the optimal
dose to be used, which maximizes HSC collection yields while min-
imizing febrile neutropenia and other toxicities, remains controver-
sial. Two historical cohorts of NHL patients who received G-CSF
and Cy at dose of either 4 g/m2 (Cy4) or 2 g/m2 (Cy2) were com-
pared.
Methods: 56 patients undergoing first mobilization with Cy and
G-CSF at a single institution between 6/06 and 9/09 were retro-
spectively analyzed. The initial Cy4 patient cohort (n5 28) was
mobilized with Cy 4gm/m2 starting on Day 1 followed by G-
CSF 10ug/kg/day starting on Day 7 and continuing until comple-
tion of apheresis. Beginning in 2/08, the Cy dose was reduced to
2gm/m2 and the G-CSF start date was moved to day 4
(Cy2 n5 28). Minimal and optimal yield was defined as collection
of $2  106 and $5  106 CD34+ cells/kg respectively. Prophy-
lactic antibiotics were given for ANC \500 to reduce risk of fe-
brile neutropenia.
Results:Minimal cell dose required for ASCT was achieved in 96%
vs. 68% of Cy4 and Cy2 patients, respectively (p5 0.0116). The one
patient failing to mobilize following Cy4, later collected a minimal
cell dose following G-CSF and plerixafor. Of the 9 patients failing
to mobilize on Cy2, six of these subsequently mobilized minimal
yields following G-CSF and plerixafor. Median number of apheresis
required was significantly lower in the Cy4 patients (2 vs.3,
p5 0.0085). The proportion of patients collecting the minimal and
optimal cell dose in 2 or fewer days of apheresis was 82% vs.39%
(p5 0.0022) and 46% vs.14% (p5 0.0186), in the Cy4 and Cy2 pa-
tients respectively. Mobilization with Cy4 was associated with a sig-
nificantly higher incidence of hospital admissions due to febrile
neutropenia (32% vs. 0%, p5 0.018), which prompted the change
from Cy4 to Cy2.
Conclusions: Although Cy4 and Cy2 are both effective HSCmobi-
lizing regimens, mobilization efficacy and toxicity vary greatly. Cy4
results in higher HSC yields requiring fewer apheresis procedures,
but this benefit is offset by increased morbidity and hospitalization.
Based on the suboptimal results with Cy 4 g/m2 and Cy 2 g/m2 mo-
bilization, we are currently exploring Cytoxan 3gm/m2 in hopes to
balance mobilization safety, efficacy and cost.Cy 4gm/m21 Cy 2gm/m21
G-CSF n5 28 G-CSF n5 28 P Value% of Patients who
achieved$ 2 x106
CD341 cells/kg in day# 282% (23/28) 39% (11/28) 0.0022% of Patients who
achieved$ 5 x 106
CD341cells/kg in# 2 days46% (13/28) 14% (4/28) 0.0186% of Patients who
achieved$ 5 x106
CD341cells/kg64% (18/28) 18% (5/28) 0.009% of Patients who
collected$ 2 x 106
CD341 cells/kg96% (27/28) 68% (19/28) 0.0116Median (range) days
of collection in all
patients2 (1-5) 3 (1-7) 0.0085% Patients hospitalized
for febrile neutropenia32% (9/28) 0% 0.018
